Compare · ALMR vs WAT
ALMR vs WAT
Side-by-side comparison of Alamar Biosciences Inc. (ALMR) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALMR and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- WAT is the larger of the two at $36.23B, about 20.1x ALMR ($1.80B).
- Over the past year, ALMR is up 17.0% and WAT is up 31.0% - WAT leads by 14.0 points.
- ALMR has been more active in the news (6 items in the past 4 weeks vs 4 for WAT).
- WAT has more recent analyst coverage (25 ratings vs 5 for ALMR).
- Company
- Alamar Biosciences Inc.
- Waters Corporation
- Price
- $25.96+3.92%
- $368.77-2.33%
- Market cap
- $1.80B
- $36.23B
- 1M return
- +29.48%
- +2.25%
- 1Y return
- +16.96%
- +30.96%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- 1995
- News (4w)
- 6
- 4
- Recent ratings
- 5
- 25
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest ALMR
- SEC Form 8-K filed by Alamar Biosciences Inc.
- Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026
- Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases
- Amendment: SEC Form SCHEDULE 13D/A filed by Alamar Biosciences Inc.
- Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research
- SEC Form SCHEDULE 13G filed by Alamar Biosciences Inc.
- Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics
- Analyst initiated coverage on Alamar Biosciences with a new price target
- BofA Securities initiated coverage on Alamar Biosciences with a new price target
- TD Cowen initiated coverage on Alamar Biosciences with a new price target
Latest WAT
- RBC Capital Mkts initiated coverage on Waters with a new price target
- Director Knight Heather was granted 63 shares, increasing direct ownership by 5% to 1,281 units (SEC Form 4)
- Director Jiang Wei was granted 67 shares, increasing direct ownership by 2% to 3,573 units (SEC Form 4)
- Waters Corporation Schedules Second Quarter 2026 Earnings Conference Call
- Bernstein resumed coverage on Waters with a new price target
- SVP Waters Analytical Sciences Carpio Robert L Iii covered exercise/tax liability with 189 shares, decreasing direct ownership by 5% to 3,426 units (SEC Form 4) (for withholding tax)
- SEC Form 11-K filed by Waters Corporation
- IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
- Piper Sandler initiated coverage on Waters with a new price target
- Waters Launches Coin Cell Differential Scanning Calorimeter (DSC) to Advance Battery Safety with Integrated Thermal, Evolved Gas, and Electrochemical Analysis